Can aprocitentan be purchased in domestic pharmacies?
Aprocitentan (Aprocitentan) is not yet officially launched in mainland China, which means that patients cannot purchase the drug directly in domestic pharmacies or medical institutions. Due to the lack of domestic registration and approval, aprexitentan has not been included in the national medical insurance system. If patients need to use it, they can only rely on formal overseas channels for procurement. This adds a certain degree of difficulty and financial burden to patients who wish to use the drug for treatment.
In the international market, aprecitentan is a new type of antihypertensive drug, mainly designed for patients with refractory hypertension. Due to its newer drug properties, the price is generally higher, which also discourages many patients. In contrast, some countries in overseas markets have approved the marketing of aprecitentan and have gained certain clinical applications and recognition, proving its efficacy and safety in controlling hypertension.
In order to reduce the financial pressure on patients, generic drugs of Aprecitentan are gradually appearing on the market. For example, the generic version produced by Lucius Pharmaceutical Factory in Laos has been officially launched locally, and the price is relatively affordable, with each box usually selling for around a few hundred yuan. Although generic drugs are low in price, their active ingredients are basically the same as the original drugs, which can meet the medication needs of patients and have become the first choice for many patients with limited economic conditions.
Generally speaking, aprexitentan is not yet available on the market in China, and patients can only obtain the original drug or generic drugs through overseas channels. The emergence of generic drugs has greatly alleviated the problem of medication costs and provided patients with more choices. If Aprexitentan is officially approved for marketing in China in the future, patients will be able to purchase and use this drug more conveniently, thereby better controlling hypertension.
Reference materials:https://go.drugbank.com/drugs/DB15059
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)